本地生产的CD19 CAR-T细胞使髓内和髓外复发性急性淋巴细胞白血病获得临床缓解
这项1b/2期研究评估了本地生产的含CD28共刺激域的CD19 CAR-T细胞治疗复发/难治性急性淋巴细胞白血病,21例入组、20例输注,中位年龄11岁,8例有髓外病变。缓解率90%,包括所有难治性髓外病灶消退;1年无事件生存率和总生存率分别为73%和90%。
要点
- 21例复发/难治性ALL入组,20例输注本地生产CD19 CAR-T,中位年龄11岁。
- 缓解率90%,包括所有难治性髓外病灶消退;1年EFS 73%、OS 90%。
- 16例发生细胞因子释放综合征,11例发生神经毒性,无毒性死亡。
核心结论
- 复发/难治性髓外急性淋巴细胞白血病患者也可能从CAR-T细胞治疗中获益。
研究设计与样本
- 1b/2期研究,评估本地生产的含CD28共刺激域的CD19 CAR-T细胞。
- 21例复发/难治性急性淋巴细胞白血病患者入组,20例接受输注,中位年龄11岁(范围5-48岁)。
主要发现
- 患者中位既往方案数为4,6例曾用贝林妥欧单抗,10例曾接受干细胞移植。
- 8例有髓外白血病累及,其中7例在淋巴清除和CAR-T前有活动性病灶。
- 18例观察到CAR-T细胞体内扩增;16例发生细胞因子释放综合征,11例发生神经毒性,无毒性死亡。
- 缓解率90%,包括所有难治性髓外病灶消退;4例缓解后复发,其中3例在CAR-T后28天为PCR-MRD阳性缓解,1例在MRD阴性缓解后21个月复发。
- 估计1年无事件生存率和总生存率分别为73%和90%。
关键数值与推荐
- 所有缓解患者均转诊至异基因造血干细胞移植。
临床怎么用
- 所有缓解患者均转诊至异基因造血干细胞移植。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autologous CD19 chimeric-antigen receptor (CAR) T cells demonstrated remarkable remission rates in relapsed and refractory acute lymphoblastic leukemia (R/R ALL). Here, we report results from a phase 1b/2 study of in-house produced CD19 CAR with a CD28 costimulatory domain. Twenty-one patients with R/R ALL were enrolled, and 20 infused. The median age was 11 years (range, 5-48). Patients had a median of 4 prior regimens, including blinatumomab in 6 and prior stem-cell transplantation in 10. In total 8 patients had extramedullary (EM) leukemic involvement, and prior to lymphodepletion and CAR 7 had active lesions, a group underrepresented in previous trials. In vivo expansion of CAR T cells was observed in 18 patients. In total 16 patients developed cytokine release syndrome, and 11 patients developed neurotoxicity, with no toxic deaths. All responding patients were referred to an allogeneic hematopoietic stem-cell transplantation. The remission rate was 90%, including resolution of all refractory EM sites. Four responding patients relapsed, 3 who had a PCR-MRD positive remission at 28 days following CAR-T cells and 1 patient 21 months after an MRD-negative response. The estimated 1-year event-free survival and overall survival are 73% and 90%, respectively. Patients with R/R EM ALL may also benefit from CAR-T cell therapy.
引用
- Jacoby E, Bielorai B, Avigdor A, et al. Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia. Am J Hematol. 2018. PMID: 30187944. doi:10.1002/ajh.25274
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。